Crystalline Cannabigerol Synthesis via Controlled Precursors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge lies in predicting and preparing crystalline forms of pharmaceutical compounds, such as cannabigerol, which are crucial for stability, bioavailability, and efficacy, but current methods are unpredictable and lack computational precision, leading to variations in polymorphic forms that can affect therapeutic effectiveness.
Innovation Solution
A novel synthetic route involving di-halo olivetol and geranyl halide in the presence of a base and solvent to produce crystalline cannabigerol, characterized by specific X-ray powder diffraction peaks, ensuring high purity and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional synthesis methods are used to prepare crystalline forms of pharmaceutical compounds, then the process is simpler, but the results are unpredictable and lack computational precision, leading to variations in polymorphic forms
Solution Approach 1:
The patent applies preliminary action by pre-selecting specific solvent systems and crystallization conditions before the actual crystallization process. The method establishes predetermined solvent combinations and temperature profiles that guide the formation of specific polymorphic forms, thereby improving predictability while maintaining relatively simple synthesis procedures.
2Adaptability or versatility
If different polymorphic forms are obtained due to unpredictable synthesis, then various solid forms may be produced, but this leads to variations in physical and chemical properties affecting therapeutic effectiveness
Solution Approach 1:
The patent employs parameter changes by systematically varying crystallization parameters such as solvent type, temperature, and concentration to control the formation of specific polymorphic forms. By establishing precise parameter ranges and conditions, the method ensures consistent production of desired solid forms with reliable therapeutic properties, thereby resolving the contradiction between versatility and reliability.
3Measurement precision
If computational prediction methods were more precise, then the number of observable polymorphs could be predicted, but currently such prediction capability is insufficient
Solution Approach 1:
The patent uses computational modeling as an intermediary tool to bridge the gap between theoretical prediction and experimental observation. The computational methods serve as a mediator that provides guidance on likely polymorphic forms, which are then validated and refined through controlled experimental crystallization, thereby compensating for the current limitations in pure computational prediction accuracy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method yields a crystalline cannabigerol with enhanced physical and chemical stability, improved bioavailability, and consistent therapeutic properties, overcoming the unpredictability of traditional synthesis methods.
Implementation Method 1
A method of preparing crystalline cannabigerol is described, involving chemical transformation of di-halo olivetol and geranyl halide
Implementation Method 2
crystalline cannabigerol comprising at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 4.73°, 9.52°, 14.30°, and 23.93° 2θ
Implementation Method 3
X-ray powder diffraction peak pattern characterization
Data Source
AI summary
The application relates to crystalline cannabigerol comprising at least one X-ray powder diffraction peak selected from the group consisting of 4.73°, 9.52°, 14.30°, and 23.93° 2Θ(each ±0.20° 2Θ), to methods of making the crystalline cannabigerol and its medical uses.